Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira

Executive Summary

Samsung Bioepis’s Ontruzant is set to be the first biosimilar version of Roche’s Herceptin on the EU market after getting the all-clear from the EMA’s CHMP on Sept. 15. The committee has also OKd another version of AbbVie’s Humira, this time from Boehringer Ingelheim.


Related Content

Orphans Dominate Products Seeking End-Of-Year Joy From CHMP
EU CHMP To Review July Rejection Of Drugs For Schizophrenia, Metastatic Breast Cancer
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea
Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod
More Questions As Biocon Pulls EU Filings For Two Biosimilars
Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts